Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 111.11% ano a ano.
Subavaliada
O PE mais recente da empresa é -9.73, em uma faixa percentil baixa de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 103.26M ações, um aumento de 16.93% em relação ao trimestre anterior.
Mantido por Paul Tudor Jones
O Super Investidor Paul Tudor Jones possui 194.83K ações desta empresa.
Alta Atividade de Mercado
A empresa tem maior interesse dos investidores, com uma taxa de giro de 20 dias de 0.46.